Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Sub-Cellular Biochemistry
|
September 10, 2014
p53 and hereditary cancer
Diana Merino, David Malkin
American Health & Drug Benefits
|
July 24, 2020
A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making
Madison M Wempe, Mark D Stewart, Daniel Glass, et al.
JCO Precision Oncology
|
October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment
Aleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Journal of Patient Experience
|
August 28, 2020
How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs)
Michael Shea, Céline Audibert, Mark Stewart, et al.
Cancer Cell
|
May 13, 2015
Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes
Yiai Tong, Diana Merino, Birgit Nimmervoll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Critical Reviews in Oncology/Hematology
|
October 9, 2020
International liquid biopsy standardization alliance white paper
Dana Connors, Jeff Allen, J D Alvarez, et al.
Oncology and Therapy
|
June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Thomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical and Translational Science
|
March 12, 2025
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Sub-Cellular Biochemistry
|
September 10, 2014
p53 and hereditary cancer
Diana Merino, David Malkin
American Health & Drug Benefits
|
July 24, 2020
A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making
Madison M Wempe, Mark D Stewart, Daniel Glass, et al.
JCO Precision Oncology
|
October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment
Aleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Journal of Patient Experience
|
August 28, 2020
How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs)
Michael Shea, Céline Audibert, Mark Stewart, et al.
Cancer Cell
|
May 13, 2015
Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes
Yiai Tong, Diana Merino, Birgit Nimmervoll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Critical Reviews in Oncology/Hematology
|
October 9, 2020
International liquid biopsy standardization alliance white paper
Dana Connors, Jeff Allen, J D Alvarez, et al.
Oncology and Therapy
|
June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Thomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical and Translational Science
|
March 12, 2025
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey, et al.
Page
of 2